Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
10 2023
Historique:
received: 19 04 2023
revised: 10 07 2023
accepted: 15 07 2023
medline: 15 9 2023
pubmed: 23 7 2023
entrez: 22 7 2023
Statut: ppublish

Résumé

This economic evaluation reports the incremental cost-utility ratio and national budget impact in France of accelerated partial breast irradiation (APBI) vs standard or hypofractionated whole breast irradiation (WBI) in breast cancer patients at low risk of local recurrence. We compared 490 women randomized to the APBI (ten fractions delivered twice daily over one week) with 488 women in the WBI arm (one fraction per day delivered five days per week over three or six weeks). We took the perspective of the French national health insurance with a three-year time horizon. The outcome was quality-adjusted life years (QALYs). The incremental cost-effectiveness ratio was estimated and uncertainty was explored by probabilistic bootstrapping. Transportation and sick leave costs were added in a sensitivity analysis and a national budget impact analysis based on the incidence of breast cancer estimates in France performed. At three years, the average cost per patient was €2,549 (±1,954) in the APBI arm and €4,468 (±1,586) in the WBI arm (p-value < 0.001), radiotherapy was the main driver of the difference between the two arms. No significant difference was found in QALYs. For an average of 60,000 new cases of breast cancer diagnosed annually in France, 28,000 would be eligible for treatment with APBI. A 100% uptake of APBI would result in a yearly30 million€ cost saving. APBI for the treatment of postmenopausal women with early-stage breast cancer is cost saving, with no difference in outcome measured by QALYs.

Identifiants

pubmed: 37480995
pii: S0167-8140(23)00379-1
doi: 10.1016/j.radonc.2023.109818
pii:
doi:

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109818

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Alicia Le Bras (A)

Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Hôtel Dieu, Clinical Research Unit Eco Ile de France, 75004, Paris, France. Electronic address: alicia.le-bras@aphp.fr.

Yazid Belkacemi (Y)

Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor University Hospital, Radiation Oncology Department and Henri Mondor Breast Center and INSERM Unit 955, Immunoregulation and Biotherapy (I-Biot) Team, The Mondor Institute for Biomedical Research (IMRB), Creteil, France. Electronic address: yazid.belkacemi@aphp.fr.

Celine Bourgier (C)

Institut de cancérologie Gustave-Roussy, Département de radiothérapie, 114 rue Édouard-Vaillant, Villejuif, France.

Isabelle Gabelle-Flandin (I)

Centre Hospitalier Universitaire Grenoble Alpes, Clinique Universitaire de Cancérologie-Radiothérapie, 38000, Grenoble, France.

Adeline Petit (A)

Institut Bergonié, Department of Radiotherapy, 229 Cours de L'Argonne, 33076, Bordeaux, France.

Philippe Guilbert (P)

Institut Godinot, Department of Radiation Therapy, Reims, France.

Julien Geffrelot (J)

Centre François Baclesse, Department of Radiation Oncology, Caen, France.

Severine Racadot (S)

Centre Léon Berard, Radiation Oncology, Lyon, France.

Eleonor Rivin Del Campo (E)

Assistance Publique-Hôpitaux de Paris (AP-HP), Tenon University Hospital, Department of Radiation Oncology, Paris 75020, France.

Chantal Hanzen (C)

Centre Henri Becquerel, UNICANCER, Department of Oncology, Rouen, France.

Claire Charra Brunaud (C)

Institut de Cancérologie de Lorraine, Department of Radiotherapy and Brachytherapy, Vandoeuvre-Lès-Nancy, France.

Guillaume Auzac (G)

Institut d'Oncologie Thoracique (IOT), Department of Radiation Oncology, Gustave Roussy, F-94805, Villejuif, France.

Thomas Lacornerie (T)

Centre Oscar Lambret, Department of Medical Physics, 59020, Lille, France.

Jerome Lemonnier (J)

Research and Development Department, UNICANCER, Paris, France.

Eric Lartigau (E)

Centres Oscar Lambret et Université de Lille, Lille, France. Electronic address: e-lartigau@o-lambret.fr.

Isabelle Durand-Zaleski (I)

Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Hôtel Dieu, Clinical Research Unit Eco Ile de France, CRESS-UMR1153, 75004, Paris, France. Electronic address: isabelle.durand-zaleski@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH